Why the Challenger Ltd share price is long term buy

The Challenger Ltd (ASX:CGF) share price looks like a good opportunity to me.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Challenger Ltd (ASX: CGF) share price has grown by 301% over the past five years, but I think there's a lot more growth to come.

Challenger is Australia's clear leader in the annuity market. It is estimated to create up to 90% of new annuities.

Here are three reasons why I think Challenger is going to be a long-term winner:

Retiring population

The large baby boomer cohort is starting to reach retirement age. People reaching retirement age are Challenger's main clients because they are looking for a place to turn their capital into a guaranteed source of income.

Over the next 20 years it's projected that the number of people over 65 will grow by 75%. Most companies on the ASX would be very happy with an increase of customers by 75%.

Challenger is very likely to be able to take advantage of this because its products are being sold through more and more distribution channels. Some of the newest channels include platforms with AMP Limited (ASX: AMP) and BT Investment Management Ltd (ASX: BTT).

Mitsui Sumitomo partnership

Challenger recently linked up with Mitsui Sumitomo Primary Life Insurance, the largest provider of foreign currency annuities in Japan. Challenger will be providing 20-year Australian dollar fixed rate annuities.

Japan has a huge retirement population and their retirees have a thirst for yield just like retirees in Australia.

Dividends

Dividends historically make up about half of total share market returns.

Challenger has been a solid dividend growth company for at least a decade. In FY17 it grew its annual dividend by 6% and it currently has a grossed-up dividend yield of 4%.

Foolish takeaway

Challenger is currently trading at 20x FY18's estimated earnings. I think this is an attractive price for a business which has such good growth prospects over the next decade.

Motley Fool contributor Tristan Harrison owns shares of Challenger Limited. The Motley Fool Australia owns shares of Challenger Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »